Pharma Focus Asia

Ribon Therapeutics Announces License Agreement with Ono Pharmaceutical Co., Ltd. to Develop and Commercialize RBN-2397 In Japan, South Korea, Taiwan and ASEAN Countries

Wednesday, February 03, 2021

Ribon Therapeutics, a clinical stage oncology company developing therapeutics targeting stress support pathways, announced it has entered into an exclusive license agreement with Ono Pharmaceutical Co., Ltd., for the development and commercialization of RBN-2397 in Japan, South Korea, Taiwan and ASEAN countries (the “Ono Territory”). RBN-2397, Ribon’s novel, first-in-class PARP7 inhibitor, is currently in Phase 1 clinical development for the treatment of cancer.

“This agreement enables us to strategically expand our program in support of Ribon’s mission to bring therapeutics targeting stress support pathways for the treatment of cancer to as many appropriate patients as possible,” said Victoria Richon, Ph.D., President and Chief Executive Officer, Ribon Therapeutics. “We believe that RBN-2397 could serve as a meaningful intervention for the treatment of tumors with PARP7 expression, which has been shown to play a key role in cancer survival. We look forward to working with Ono, a global leader in immuno-oncology, to unlock the potential of RBN-2397 for patients in Japan, South Korea, Taiwan and ASEAN countries.”

“We are pleased to be collaborating with Ribon, a pioneer in the development of novel precision oncology drugs targeting stress support pathways”, said Gyo Sagara, President, Representative Director of Ono. “We believe that RBN-2397 could have a profound impact on patients with cancer, given the potential of the therapy’s dual mechanism to suppress tumor growth and enhance immune reaction to tumor cells. We look forward to developing RBN-2397 with Ribon by harnessing our experience and expertise in oncology.”

Under the terms of the agreement, Ribon will receive a one-time upfront payment of approximately $16.3 million from Ono. In addition, Ribon is eligible to receive up to a potential of approximately $132 million at current exchange rates based on the achievement of certain regulatory and commercial milestones, as well as tiered royalties ranging from the high single digits to low teens on net sales of RBN-2397 in the Ono Territory. In exchange, Ono will have the exclusive rights to develop and commercialize RBN-2397 in the Ono Territory. Additionally, Ono will have the right to participate in global clinical studies of RBN-2397 by bearing the costs of such studies in the Ono Territory.

Ribon retains all rights to develop and commercialize RBN-2397 worldwide outside of the Ono Territory, including the United States, the European Union and China.

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024